Pharmaceutical News

RSS

Ghrelin has potential to stimulate alcohol craving, study reveals

Ghrelin is a hormone released by the stomach and it stimulates appetite and food intake. Alcohol is commonly viewed as a psychoactive substance that primarily affects brain function, but it is also a highly caloric food.

30 Oct 2014

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride Tablets USP, 23 mg, the generic equivalent to Eisai Inc.'s Aricept 23mg.

30 Oct 2014

Study: Certain prostate cancer medications linked to cardiac death risk

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs.

30 Oct 2014

UBC researchers set to develop universal antidote to simplify use of heparin

Heparin, the life saving blood thinner used in major surgeries and treatment of heart diseases, is a complicated drug but a research team from the University of British Columbia has set out to make its use a lot safer by developing a universal antidote.

29 Oct 2014

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

The uncontrolled growth of cancer cells arises from their ability to hijack the cell’s normal growth program and checkpoints. Usually after therapy, a second cancer-signaling pathway will open after the primary one shuts down — creating an ingenious escape route for the cancer cell to survive. The answer, say Case Western Reserve researchers, is to anticipate and block that back-up track by prescribing two drugs from the start.

29 Oct 2014

Penn Medicine-developed drug gets FDA orphan status for PNH treatment

A Penn Medicine-developed drug has received orphan status from the Food and Drug Administration (FDA) this month for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis.

28 Oct 2014

Generic aromatase inhibitors increase breast cancer treatment adherence by 50%

Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor-positive tumors, about one-half of patients fail to take their medications as directed. A new study by Columbia University Medical Center researchers has found that the introduction of generic aromatase inhibitors (the most common type of hormone therapy), which are considerably less expensive than their brand name counterparts, increased treatment adherence by 50 percent.

28 Oct 2014

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder.

28 Oct 2014

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'.

28 Oct 2014

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand.

27 Oct 2014

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month.

27 Oct 2014

Digoxin drug may be adaptable for ALS treatment, study suggests

Digoxin, a medication used in the treatment of heart failure, may be adaptable for the treatment of amyotrophic lateral sclerosis (ALS), a progressive, paralyzing disease, suggests new research at Washington University School of Medicine in St. Louis.

27 Oct 2014

CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma Corp. today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited, the originator of tosedostat, and Chroma Therapeutics Ltd., through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America.

27 Oct 2014

Virginia Tech professor developing vaccine that could help smokers overcome nicotine addiction

A Virginia Tech professor is working on a vaccine that could help smokers conquer their nicotine addiction, making many smoking-related diseases and deaths relics of the 21st century.

27 Oct 2014

WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

WHO convened a meeting with high-ranking government representatives from Ebola-affected countries and development partners, civil society, regulatory agencies, vaccine manufacturers and funding agencies yesterday to discuss and agree on how to fast track testing and deployment of vaccines in sufficient numbers to impact the Ebola epidemic.

26 Oct 2014

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

Analgesics, anti-inflammatory drugs have beneficial effect on treatment of depression

Ordinary over the counter painkillers and anti-inflammatory drugs purchased from pharmacies may also be effective in the treatment of people suffering of depression.

22 Oct 2014

Novel way for treating non-cardiac chest pain due to esophageal hypersensitivity

Chest pain doesn't necessarily come from the heart. An estimated 200,000 Americans each year experience non-cardiac chest pain, which in addition to pain can involve painful swallowing, discomfort and anxiety. Non-cardiac chest pain can be frightening for patients and result in visits to the emergency room because the painful symptoms, while often originating in the esophagus, can mimic a heart attack.

22 Oct 2014

Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced the opening of the Crown Bioscience US Research Center to be located at the David H. Murdock Research Institute (DHMRI), in Kannapolis, N.C. The new center, which will open in the 3rd quarter of 2014, represents significant U.S. market expansion for Crown.

21 Oct 2014

Beacon Hill Pharma opens second location in Wakefield, MA

Beacon Hill Pharma, Beacon Hill Staffing Group's pharma specialty division, opened a second location this past month just north of Boston in Wakefield, MA. This comes just one month after Beacon Hill

21 Oct 2014

Pharmaceutical News

Ghrelin has potential to stimulate alcohol craving, study reveals

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

Study: Certain prostate cancer medications linked to cardiac death risk

UBC researchers set to develop universal antidote to simplify use of heparin

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

Penn Medicine-developed drug gets FDA orphan status for PNH treatment

Generic aromatase inhibitors increase breast cancer treatment adherence by 50%

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

Digoxin drug may be adaptable for ALS treatment, study suggests

CTI BioPharma acquires worldwide rights to tosedostat

Virginia Tech professor developing vaccine that could help smokers overcome nicotine addiction

WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Analgesics, anti-inflammatory drugs have beneficial effect on treatment of depression

Novel way for treating non-cardiac chest pain due to esophageal hypersensitivity

Crown Bioscience announces U.S. expansion with new translational oncology center

Beacon Hill Pharma opens second location in Wakefield, MA

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News